<DOC>
	<DOCNO>NCT00859339</DOCNO>
	<brief_summary>This trial investigate activity sunitinib combine cisplatin gemcitabine follow radical cystectomy patient Transitional Cell Carcinoma ( TCC ) Bladder .</brief_summary>
	<brief_title>Neoadjuvant Cisplatin , Gemcitabine , Sunitinib Malate + Radical Cystectomy TCC</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Gemcitabine ( 1000 mg/m2 ) IV day 1 8 - Cisplatin ( 70 mg/m2 ) IV day 1 - Sunitinib malate ( 37.5 mg ) oral daily day 1-14 The treatment regimen administer four , 21-day , cycle follow radical cystectomy perform sooner 2 week within 6 week last dose sunitinib malate . ECOG performance status 0 1 Hematopoietic : - Absolute Neutrophil Count ( ANC ) &gt; 1.5 K/mm3 [ ( IS ) : 1.5 x 109/L ] - Platelets &gt; 100 K/mm3 [ ( IS ) : 100 x 109/L ] - Hemoglobin ( Hgb ) &gt; 9.0 g/dL [ ( IS ) : 90 g/L ] Hepatic : - Total bilirubin &lt; 1.5 x Upper Limit Normal ( ULN ) - Aspartate aminotransferase ( AST ) ≤ 2.5 x ULN - Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Renal : - Calculated creatinine clearance &gt; 60 cc/min Cardiovascular : - No uncontrolled angina , congestive heart failure myocardial infarction coronary/peripheral artery bypass graft within 6 month prior registration protocol therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological proof muscleinvasive transitional cell carcinoma bladder ( stage IIIII ) evidence metastatic disease ( focal squamous and/or adenocarcinoma differentiation allow , sarcomatoid smallcell component allow ) . Patient degree fixation pelvic sidewall eligible . Must willing undergo cystoscopy tumor block available prior registration protocol therapy . Eligible radical cystectomy per attend urologist . Prior radiation therapy bone marrow allow &lt; 25 % marrow , must complete least 6 month prior registration protocol therapy Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year time consent . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 6 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . No prior radiotherapy pelvis . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , Gleason &lt; grade 7 prostate cancer , cancer patient diseasefree least 5 year . No treatment investigational agent within 30 day prior registration protocol therapy . No cerebrovascular accident transient ischemic attack within 6 month prior registration protocol therapy . No evidence pulmonary embolism within 6 month prior registration protocol therapy . No uncontrolled hypertension ( &gt; 150/100 mm Hg despite optimal medical therapy ) . No evidence ongoing cardiac dysrhythmias NCI CTCAE Version 3.0 grade 2 . No history uncontrolled/untreated thyroid dysfunction . No prolonged QTc interval ( &gt; 450 msec ) preentry electrocardiogram obtain within 28 day prior register study . Patients warfarin ( &gt; 2mg ) thrombosis must able willing switch low molecular weight heparin prior registration protocol therapy . No use drug proarrhythmic potential ( terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide flecainide ) within 7 day prior registration protocol therapy . No use CYP3A4 inhibitor ( see section 5.3 list ) within 7 day registration protocol therapy . No use CYP3A4 inducer ( see section 5.3 list ) within 14 day registration protocol therapy . No use amiodarone ( CYP3A4 inhibitor ) within 6 month registration protocol therapy . Females must breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>TCC</keyword>
</DOC>